1. Home
  2. ERO vs NAMS Comparison

ERO vs NAMS Comparison

Compare ERO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ero Copper Corp.

ERO

Ero Copper Corp.

HOLD

Current Price

$27.70

Market Cap

3.2B

Sector

N/A

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$31.98

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ERO
NAMS
Founded
2016
2019
Country
Canada
Netherlands
Employees
N/A
100
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.5B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ERO
NAMS
Price
$27.70
$31.98
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$36.50
$46.75
AVG Volume (30 Days)
975.3K
765.5K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$51.94
$17.96
Revenue Next Year
$2.43
$540.65
P/E Ratio
$22.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.99
$16.79
52 Week High
$39.80
$42.00

Technical Indicators

Market Signals
Indicator
ERO
NAMS
Relative Strength Index (RSI) 45.99 46.07
Support Level $23.01 $29.73
Resistance Level $32.48 $37.25
Average True Range (ATR) 1.40 1.65
MACD -0.13 -0.17
Stochastic Oscillator 21.67 7.59

Price Performance

Historical Comparison
ERO
NAMS

About ERO Ero Copper Corp.

Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: